Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

Forbes contributors publish independent expert analyses and insights. Davey Winder is a veteran cybersecurity writer, hacker and analyst. Update, July 30, 2025: This story, originally published on ...

In his 1960 book Theory and Design in the First Machine Age, the critic and historian Reyner Banham presciently noted a growing chasm between technological change and the capacity of designers to ...

The data extortion group World Leaks has just leaked a huge 1.3-terabyte trove of data stolen from US computer maker Dell Technologies Inc. Dell confirmed a breach earlier, saying that it impacted the ...

Access detailed historical stock prices, including daily closing prices, for PBL:CA. Analyze past performance trends, track price movements, and explore historical data to inform your investment ...

When you’ve lost essential files that you absolutely must restore, you need the best data recovery software available. It pays to shop around. I’ve reviewed all the top brands and found that prices, ...

“Why you can trust Digital Trends – We have a 20-year history of testing, reviewing, and rating products, services and apps to help you make a sound buying decision. Find out more about how we test ...

There is no current Support Plan to trigger a buy of this stock at this time. This usually means that there are no clear support levels at this time, so buying the stock as it falls could be ...

Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, ...